KERENDIA® Meets Phase III Primary Endpoint in CKD Study
KERENDIA® (finerenone) met its primary endpoint demonstrating a statistically significant improvement vs. placebo in the estimated glomerular filtration rate (eGFR) slope from baseline to Month 32...